NEW YORK, April 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the partial exercise of the over-allotment option granted to the underwriters to purchase an additional 1,500,000 shares of its common stock, at a price to the public of $0.50 per share, in connection with the Company's recently announced underwritten public offering of 20,000,000 shares of common stock, bringing total gross proceeds from the offering to $10,750,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
NeoStem Announces Partial Exercise Of Underwriters' Over-Allotment Option
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts